Moderna and Pfizer lead the race to develop a Covid-19 vaccine

Here’s how Pfizer, Moderna, Novavax compare in race for COVID-19 vaccine

Moderna and Pfizer lead the race to develop a Covid-19 vaccine

Two potential Covid-19 vaccines being developed by Moderna and Pfizer have entered the final stages of trials. Under the optimistic scenario, they will enter the market for widespread use by the end of the year.

These are the first trials of a coronavirus vaccine that have made it to an advanced stage. Research is actively supported by the administration Donald Trump, which strengthens hopes for its mass production and distribution, if the drug is effective.

Against the backdrop of news data, shares Moderna yesterday grew by 9%, and Pfizer by 1.6%.

Both vaccines are based on new technology that accelerates the development and production of samples, but has not yet been widely used in medicine..

The essence of the drug lies in the principle of the so-called «synthetic messenger RNA (mRNA)», which teaches the immune system to recognize and neutralize the coronavirus.

Moderna has received almost $ 1 billion from the American authorities, which are funding several projects at once to create a drug for Covid-19 as part of its Operation Warp Speed ​​program..

Pfizer signs an agreement to sell vaccines for 50 million people to the US government for about $ 2 billion if the vaccine is effective.

To date, more than 150 potential vaccines are in various stages of development, and about two dozen drugs are already undergoing human trials..

Johnson & Johnson Launches US Clinical Trials This Week, May Move To The Next Phase Of The Study As Of September. British drug maker AstraZeneca Plc said it will begin large-scale trials of its vaccine this summer, which it is developing in collaboration with researchers at Oxford University..

Moderna and Pfizer lead the race to develop a Covid-19 vaccine

«Distribution of a safe and effective vaccine by the end of 2020 – this is a difficult but correct goal», – said the director of the National Institutes of Health (NIH) Francis Collins.

Companies are ramping up production while testing is in progress to respond as quickly as possible to a threat from outside. a virus that is still spreading rapidly around the world. Covid-19 has killed almost 650 thousand people and caused tremendous damage to the global economy.

Moderna could have tens of millions of doses ready in a short time if the vaccine is found to be safe and effective, Collins told reporters..

Anthony Fauci, top U.S. official for infectious diseases, said Moderna test results could be available by November or even earlier.

Pfizer said that if the study is successful, it could get regulatory approval in October and deliver vaccines for 50 million patients, two doses each, by the end of the year..

Pfizer Aims To Deliver About 1.3 Billion Doses By The End Of 2021.